Key facts
- This page summarizes Christopher Benecchi's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Feb 2023, 15:10.
Christopher Benecchi - 03 Feb 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- SAGE
- Reported as of
- 03 Feb 2023
- Net transaction value
- -$93,575
- SEC form
- 4
- Accepted by SEC
- 07 Feb 2023, 15:10:45 UTC
- Prior SEC filing
- 21 Jun 2022
- Next SEC filing
- 15 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Anne Marie Cook, as Attorney-in-Fact for Christopher Benecchi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Benecchi filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 07 Feb 2023.
Change
- Previous filing in this sequence was filed on 21 Jun 2022.
- Current net transaction value: -$93,575.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SAGE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +6,750
- Change %
- +1073%
- Price
- $0.000000
- Shares after
- 7,379
- Date
- 03 Feb 2023
- Ownership
- Direct
- Footnotes
- F1, F2
SAGE
transaction
Common Stock
Tax liability
- Transaction value
- $93,575
- Shares
- -2,119
- Change %
- -29%
- Price
- $44.16
- Shares after
- 5,260
- Date
- 03 Feb 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On October 1, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 22,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 6,750 shares.
Footnote F2
Reflects beneficial ownership balance which includes 414 shares purchased on June 30, 2022 and 215 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.